DoD, Ovarian Cancer, Pilot Award

The Ovarian Cancer Pilot Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs as part of the Ovarian Cancer Research Program. This initiative originates from congressional appropriations intended to support high-impact biomedical research addressing ovarian cancer, with a long-standing investment history exceeding hundreds of millions of dollars since its inception in the late 1990s. The program is aligned with a mission to prevent, detect, treat, and ultimately cure ovarian cancer while improving survivorship and quality of life, particularly for service members, veterans, their families, and the broader population affected by this disease. The primary objective of the Pilot Award is to fund innovative, early-stage research that challenges existing paradigms or introduces new conceptual approaches in ovarian cancer science. The program explicitly prioritizes innovation over incremental advances, requiring applicants to propose work that expands or modifies current thinking. While preliminary data are permitted, they are not required, reinforcing the exploratory nature of the award. Funded projects are expected to generate foundational data that can lead to future, more extensive research efforts. Clinical trials are explicitly excluded from funding under this mechanism. Funding under this opportunity is capped at a total of 350000 dollars per award, with an anticipated total program allocation of approximately 4.55 million dollars supporting around 13 awards. The maximum period of performance is two years. Allowable costs include research expenses and limited travel for collaboration and dissemination, while restrictions prohibit funding for tuition, excessive travel, and any clinical trial-related costs. Indirect costs are permitted in accordance with negotiated institutional rates. There is no requirement for cost sharing or matching funds. Eligibility for the program is broad and inclusive, encompassing domestic and international organizations across public and private sectors, including academic institutions, government entities, nonprofit organizations, and for-profit entities. Principal Investigators must be affiliated with an eligible organization and may range from postdoctoral-level researchers to senior investigators. Each investigator may submit only one application as a Principal Investigator under this mechanism. Awards are made to organizations rather than individuals, and collaborative, multidisciplinary research efforts are strongly encouraged. The application process follows a two-step submission structure. Applicants must first submit a blinded pre-application through the Electronic Biomedical Research Application Portal. This pre-application must not include any identifying information about the investigator or institution and is limited in length and content. Based on the evaluation of these submissions, selected applicants are invited to submit a full application through either Grants.gov or the portal, depending on organizational type. Full applications include detailed narratives, abstracts, statements of work, and supporting documentation such as letters of support and data-sharing plans. Applications undergo a rigorous two-tier review process consisting of peer review and programmatic review. Evaluation criteria include research strategy, feasibility, innovation, and potential impact on ovarian cancer outcomes. Additional considerations include personnel qualifications, budget appropriateness, and institutional support. The program emphasizes alignment with designated areas of emphasis, such as novel therapeutics, early detection strategies, survivorship improvements, and understanding disease biology. The timeline for this funding opportunity includes a pre-application deadline in mid-July, followed by invitations to submit full applications in August, and a final application deadline in early October. Peer review is conducted in November, with programmatic review in January and funding decisions typically finalized thereafter. Awards are expected to be issued by late September of the following year, with funds available for use through a defined federal funding period.

Ensure strict compliance with blinded pre-application rules; prioritize innovation over incremental research; align proposal with areas of emphasis; clearly articulate impact on ovarian cancer outcomes